Take off with Aurinia Pharmaceuticals Inc. (AUPH): Get ready for trading

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock jumped 0.47% on Friday to $8.50 against a previous-day closing price of $8.46. With 2.02 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.82 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.96 whereas the lowest price it dropped to was $8.39. The 52-week range on AUPH shows that it touched its highest point at $33.97 and its lowest point at $7.70 during that stretch. It currently has a 1-year price target of $23.31. Beta for the stock currently stands at 0.98.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AUPH was down-trending over the past week, with a drop of -0.93%, but this was down by -31.29% over a month. Three-month performance dropped to -23.56% while six-month performance fell -51.81%. The stock lost -36.09% in the past year, while it has lost -62.83% so far this year. A look at the trailing 12-month EPS for AUPH yields -1.27 with Next year EPS estimates of -0.14. For the next quarter, that number is -0.22. This implies an EPS growth rate of -61.40% for this year and 88.40% for next year.

Float and Shares Shorts:

At present, 141.68 million AUPH shares are outstanding with a float of 132.66 million shares on hand for trading. On Jul 14, 2022, short shares totaled 13.84 million, which was 9.76% higher than short shares on Jun 14, 2022. In addition to Mr. Peter S. Greenleaf M.B.A. as the firm’s Pres, CEO & Director, Mr. Joseph M. Miller CPA serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 31.17% of AUPH’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 20.42% of AUPH, in contrast to 11.29% held by mutual funds. Shares owned by individuals account for 0.36%. As the largest shareholder in AUPH with 3.73% of the stake, Fidelity Management & Research Co holds 5,291,226 shares worth 5,291,226. A second-largest stockholder of AUPH, BlackRock Fund Advisors, holds 5,202,983 shares, controlling over 3.67% of the firm’s shares. Morgan Stanley & Co. LLC is the third largest shareholder in AUPH, holding 2,654,130 shares or 1.87% stake. With a 2.11% stake in AUPH, the iShares Russell 2000 ETF is the largest stakeholder. A total of 2,987,165 shares are owned by the mutual fund manager. The Fidelity Advisor Series I -Growth, which owns about 1.29% of AUPH stock, is the second-largest Mutual Fund holder. It holds 1,825,600 shares valued at 18.35 million. iShares Russell 2000 Growth ETF holds 0.75% of the stake in AUPH, owning 1,059,053 shares worth 10.64 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AUPH since 8 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AUPH analysts setting a high price target of $30.00 and a low target of $15.00, the average target price over the next 12 months is $23.31. Based on these targets, AUPH could surge 252.94% to reach the target high and rise by 76.47% to reach the target low. Reaching the average price target will result in a growth of 174.24% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AUPH will report FY 2022 earnings on 03/09/2023. Analysts have provided yearly estimates in a range of -$0.48 being high and -$0.90 being low. For AUPH, this leads to a yearly average estimate of -$0.68. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Aurinia Pharmaceuticals Inc. surprised analysts by -$0.00 when it reported -$0.27 EPS against a consensus estimate of -$0.27. The surprise factor in the prior quarter was $0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.19 and the low estimate is -$0.25. The average estimate for the next quarter is thus -$0.22.

Summary of Insider Activity:

Insiders traded AUPH stock several times over the past three months with 2 Buys and 0 Sells. In these transactions, 20,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 96 while that of sell transactions has risen to 104 over the past year. The total number of shares bought during that period was 2,955,492 while 3,752,929 shares were sold.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]